2.31 Listener Questions, Responsibility of Reviewers, & Duration of Response with Dr. Bishal Gyawali

Plenary Session

Vinay Prasad, MD MPH

Health, Oncology, Policy, Medicine, Science & Medicine

4.8 • 799 Ratings

🗓️ 7 January 2020

⏱️ 40 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

This week we answer a few questions: the first is from Patreon backer, Harry Hong, on Kaplan-Meier curves. The second is from a student at Mount Sinai Medical School who reached out with some ethical questions they had after the ASH annual meeting on the obligations and responsibilities of peer reviewers. Finally, we end the episode with an interview with Dr. Bishal Gyawali of Queens University in Kingston, Ontario, Canada on his new paper out today in the Journal of the National Comprehensive Cancer Network titled "Response Rates and Durations of Response for Biomarker-Based Cancer Drugs in Nonrandomized Versus Randomized Trials". Durations of Response: doi.org/10.6004/jnccn.2019.7345 Vinay's new book, Malignant: www.amazon.com/Malignant-Policy-…cer/dp/1421437635 Back us on Patreon! www.patreon.com/plenarysession

Transcript

Click on a timestamp to play from that location

0:00.0	Welcome to Plenary Session.
0:07.0	I'm your host, Dr. Vinay Prasad.
0:10.0	I'm a practicing hematologist, oncologist, and I'm associate professor of medicine.
0:14.0	I'm interested in issues at the intersection of medicine, oncology, and health policy, and that's what you're going to get on this podcast.
0:22.2	Welcome to Season 2.
0:25.1	This week on Plenary Session, we have a couple of things for you. First, we have a question
0:29.8	from Harry Hong, who is, in fact, a Patreon backer. Thank you, Harry. Next, I have a couple
0:35.7	questions from a student at Mount Sinai Medical School
0:38.4	who posed this to me during the Ash holiday, and I'll answer that on this week's podcast.
0:43.7	And finally, we have joined via Skype, Bishall Gawali, who is going to talk to us about his paper
0:49.8	out today in the JNCCN, looking at whether or not targeted drugs maintain their response rate
0:56.0	and their duration of response between phase two and phase three testing.
1:00.4	You won't want to miss this discussion, so stay tuned.
1:04.1	But first, a bit of a professional update.
1:07.3	I let people know on Twitter, and I guess I will let you know here on the podcast, that this
1:12.6	may, I will be moving Plenary Session HQ from Oregon to San Francisco.
1:18.9	I'll be an associate professor of medicine in the Department of Epidemiology and Biostatistics
1:22.7	at UCSF. I will be continuing my oncology clinical practice and hope to see patients with a diverse range
1:31.3	of classical, hematologic, and malignant problems there at San Francisco.
1:36.4	I look forward to continuing this podcast.
1:38.5	I've spent a lot of time in San Francisco over the years.
1:40.2	I know I'm going to enjoy it, but I will also miss one of my favorite cities in the world,
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from Vinay Prasad, MD MPH, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of Vinay Prasad, MD MPH and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.